On August 4, 2022, Gelesis, Inc. (the “Subsidiary”), a subsidiary of Gelesis Holdings, Inc. (“Gelesis”), entered into an Amendment (the “Amendment”) to the License, Collaboration and Supply Agreement, dated June 18, 2020 (the “Original Agreement”), by and between the Subsidiary and CMS Bridging DMCC, an affiliate of CMS Medical Venture Investment (HK) Limited (“CMS”) that governs the license of Gelesis intellectual property to CMS in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan), Singapore and United Arab Emirates (collectively, the “CMS Territory”), and the supply of Plenity to CMS for sale in the CMS Territory. Pursuant to the Amendment, the one-time, non-refundable, and non-creditable regulatory approval milestone payment of $5.0 million provided for in the Original Agreement became immediately payable. In addition, the Amendment expands the CMS Territory to include Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Thailand and Vietnam and provides that the minimum annual royalty term for CMS territory will commence January 2024 (rather than January 2022, as previously provided under the Original Agreement) and extend through the expiration date of the amended agreement.